27 research outputs found

    Fumarase is involved in DNA double-strand break resection through a functional interaction with Sae2

    No full text
    10.1007/s00294-017-0786-4Current Genetics643697-71

    Case-control study on the role of enterotoxigenic Bacteroides fragilis as a cause of diarrhea among children in Kolkata, India.

    Get PDF
    A total of 874 fecal specimens (446 diarrheal cases and 428 controls) from diarrheal children admitted in the Infectious Diseases Hospital, Kolkata and age and sex matched asymptomatic subjects from an urban community were assessed for the prevalence of enterotoxigenic Bacteroides fragilis (ETBF). Isolates of B. fragilis were tested for the presence of enterotoxin gene (bft) by PCR. The detection rate of ETBF was 7.2% (63 of 874 specimens) that prevailed equally in diarrheal cases and controls (7.2% each; 32 of 446 cases and 31 of 428 controls). Male children up to one year age group was significantly (p<0.05) associated with ETBF infection as compared to children > 2 years of age in cases and controls. In 25 ETBF isolates, the bft gene was genotyped using PCR-RFLP and only two alleles were identified with prevalence rate of 40% and 60% for bft-1 and bft-3, respectively. All the ETBF isolates were susceptible for chloramphenicol and imipenem but resistant to clindamycin (48%), moxifloxacin (44%) and metronidazole (32%). Resistance of ETBF to moxifloxacin (44%) and metronidazole is an emerging trend. Pulsed-field gel electrophoresis (PFGE) revealed that majority of the ETBF isolates are genetically diverse. In the dendrogram analysis, two clusters were identified, one with ETBF resistant to 5-8 antimicrobials and the other cluster with metronidazole and moxifloxacin susceptible isolates from diarrheal cases. To our knowledge, this is the first detailed report on ETBF from India indicating its clinical importance and molecular characteristics

    All differentially expressed CSRs between breast cancer and each healthy tissue.

    No full text
    Each sheet is named according to the comparison for which the differential CSR expression results are represented. E.g., BRCA vs skin shows the results between breast tumour profile by the TCGA and all healthy tissues profile by the GTEx project. (XLSX)</p

    Differentially expressed CSRs between PAM50 subtypes of breast cancer.

    No full text
    The sheets are named according to the comparison for which the differential expression CSRs results are represented. E.g., BRCA Basal-Vs-BRCA HER2 shows the results of Basal-like breast cancer subtype and HER2-positive breast cancer. (XLSX)</p

    Comparison of the differentially expressed CSR transcripts between each pair of PAM50 breast cancer subtypes.

    No full text
    The two plots show the comparison made for the TCGA primary tumours, whereas the two bottom plots show the comparison for the GDSC breast cancer cell lines. The plots on the left column show the upregulated transcripts between each comparison, and those on the right show the downregulated transcripts between each comparison.</p

    Spreadsheet showing the information that we collated from various results, including clinical trials information from www.clinicaltrials.gov of drug targets for drugs used applied in clinical trials that were retrieved from the Pharos database and Drug Gene Interaction database and the CSR transcript levels of the tissues in which are adverse events that are reported in the clinical trials occurred.

    No full text
    Spreadsheet showing the information that we collated from various results, including clinical trials information from www.clinicaltrials.gov of drug targets for drugs used applied in clinical trials that were retrieved from the Pharos database and Drug Gene Interaction database and the CSR transcript levels of the tissues in which are adverse events that are reported in the clinical trials occurred.</p
    corecore